📊 CLDX Key Takeaways
Is Celldex Therapeutics, Inc. (CLDX) a Good Investment?
Celldex Therapeutics is a pre-revenue biotech company in severe financial distress with $1.5M in revenue (down 78% YoY), massive operating losses of $287.4M, and negative free cash flow of $213.7M. The company is burning cash at an unsustainable rate with only $28.9M in liquidity against $210.9M in negative operating cash flow, indicating critical runway concerns despite strong balance sheet equity.
Celldex’s fundamentals are dominated by a clinical-stage biotech profile with minimal revenue, extremely negative margins, and very large operating and free cash flow losses. While the balance sheet shows low leverage, the combination of a 78% revenue decline and roughly $211M of operating cash burn against only $28.87M of cash creates a weak near-term financial picture and raises sustainability concerns.
Why Buy Celldex Therapeutics, Inc. Stock? CLDX Key Strengths
- Strong balance sheet with $527.2M in stockholders' equity providing strategic cushion
- Minimal debt burden with zero long-term debt and clean capital structure
- Adequate current ratio of 10.49x indicating short-term liquidity despite cash burn
- Debt-free capital structure with 0.00x debt-to-equity
- Very strong reported liquidity ratios at 10.49x current and quick ratio
- Large equity base of $527.16M relative to liabilities of $55.82M
CLDX Stock Risks: Celldex Therapeutics, Inc. Investment Risks
- Catastrophic cash burn of $210.9M from operations with only $28.9M cash remaining; estimated runway of less than 2 months
- Revenue collapse of 78% YoY to $1.5M suggests failed commercialization or terminated programs
- Unsustainable negative margins with -18,600% operating margin and -16,748% net margin indicating core business model failure
- Revenue base is very small and fell 78.0% year over year
- Profitability is extremely weak with operating margin of -18599.8% and net margin of -16748.0%
- Cash burn is severe, with -$210.94M operating cash flow and -$213.66M free cash flow
Key Metrics to Watch
- Cash burn rate and quarterly cash position relative to remaining runway
- Revenue stabilization or recovery from current $1.5M annualized rate
- Pipeline milestone announcements and clinical trial progression for biotech programs
- Cash runway versus quarterly operating cash burn
- Revenue durability and any improvement in operating loss trend
Celldex Therapeutics, Inc. (CLDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.49x current ratio provides a solid financial cushion.
CLDX Profit Margin, ROE & Profitability Analysis
CLDX vs Healthcare Sector: How Celldex Therapeutics, Inc. Compares
How Celldex Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Celldex Therapeutics, Inc. Stock Overvalued? CLDX Valuation Analysis 2026
Based on fundamental analysis, Celldex Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Celldex Therapeutics, Inc. Balance Sheet: CLDX Debt, Cash & Liquidity
CLDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Celldex Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 5% decline. The most recent EPS of $-2.92 indicates the company is currently unprofitable.
CLDX Revenue Growth, EPS Growth & YoY Performance
CLDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.4M | -$32.8M | $-0.64 |
| Q2 2025 | $730.0K | -$32.8M | $-0.54 |
| Q1 2025 | $156.0K | N/A | $-0.56 |
| Q3 2024 | $1.5M | N/A | $-0.64 |
| Q2 2024 | $268.0K | N/A | $-0.54 |
| Q1 2024 | $156.0K | N/A | $-0.56 |
| Q3 2023 | $407.0K | N/A | $-0.57 |
| Q2 2023 | $163.0K | N/A | $-0.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Celldex Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CLDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Celldex Therapeutics, Inc. (CIK: 0000744218)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLDX
What is the AI rating for CLDX?
Celldex Therapeutics, Inc. (CLDX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLDX's key strengths?
Claude: Strong balance sheet with $527.2M in stockholders' equity providing strategic cushion. Minimal debt burden with zero long-term debt and clean capital structure. ChatGPT: Debt-free capital structure with 0.00x debt-to-equity. Very strong reported liquidity ratios at 10.49x current and quick ratio.
What are the risks of investing in CLDX?
Claude: Catastrophic cash burn of $210.9M from operations with only $28.9M cash remaining; estimated runway of less than 2 months. Revenue collapse of 78% YoY to $1.5M suggests failed commercialization or terminated programs. ChatGPT: Revenue base is very small and fell 78.0% year over year. Profitability is extremely weak with operating margin of -18599.8% and net margin of -16748.0%.
What is CLDX's revenue and growth?
Celldex Therapeutics, Inc. reported revenue of $1.5M.
Does CLDX pay dividends?
Celldex Therapeutics, Inc. does not currently pay dividends.
Where can I find CLDX SEC filings?
Official SEC filings for Celldex Therapeutics, Inc. (CIK: 0000744218) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLDX's EPS?
Celldex Therapeutics, Inc. has a diluted EPS of $-3.90.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLDX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Celldex Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLDX stock overvalued or undervalued?
Valuation metrics for CLDX: ROE of -49.1% (sector avg: 15%), net margin of -16,748.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLDX stock in 2026?
Our dual AI analysis gives Celldex Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLDX's free cash flow?
Celldex Therapeutics, Inc.'s operating cash flow is $-210.9M, with capital expenditures of $2.7M. FCF margin is -13,829.1%.
How does CLDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -16,748.0% (avg: 12%), ROE -49.1% (avg: 15%), current ratio 10.49 (avg: 2).